Biotechnology companies dedicated

Since the development in the 1970s of molecular tools enabling the production of proteins and peptides in sufficient quantities for therapeutic purposes, dedicated biotechnology companies have been examining, refining, and developing these technologies for commercialization. This... 

In contrast with the postwar strategies of the established drug industry, dedicated biotechnology companies were created to exploit the commercial potential of technological innovation and ideas. Therefore... 

For an examination of the competitiveness of U.S.-based dedicated biotechnology companies, see OTA s recent report on the subject... 

A relatively small number of biotechnology companies operate in the field of recombinant proteins production in plants (Table 6.4). This small number represents roughly one-third of approximately 60 dedicated plant biotechnology companies - an unfavorable comparison to the several hundred small and medium-sized businesses that use bacterial, yeast or animal-based expression platforms and operate in the sector of red biotechnology. The number of plant-made recombinant proteins that have reached the market is also very limited, but has a healthy tendency to grow. 

The observation of multiple charging of proteins in electrospray ionization attracted much attention all major instrument manufacturers introduced an API system to be used in combination with an electrospray interface. At the same time, it was found that electrospray ionization is not only suitable for the mass analysis of large molecules, but is also a very efficient ionization technique of small polar or ionic molecules, e.g. drugs and their metabolites. In the past few years, hundreds of dedicated API-MS systems equipped with electrospray and APCI interfaces have found their way into many different laboratories, especially within pharmaceutical companies and biochemistry/biotechnology laboratories. 

---